CNMD CONMED Corp
Debt Financing ·
CONMED will repurchase its 2.250% convertible notes due 2027 for cash under a purchase agreement dated June 3, 2026, with closing set for June 15, 2026. The principal and cash amounts sit in an exhibit the filing does not show.
The first omnibus amendment adds Term A-2 commitments of $450,000,000 under the company's existing credit agreement, with JPMorgan Chase Bank, N.A. as administrative agent.
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $1.37 billion | $1.31 billion |
| Research and development | $55.9 million | $54.4 million |
| Net income (loss) | $47.1 million | $132.4 million |
| Cash from operations | $170.7 million | $167.0 million |
| Cash and equivalents | $40.8 million | $24.5 million |
Our latest story on this, dated Jun 3, 2026: "CONMED agrees to buy back 2.250% convertible notes due 2027 for cash". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Jun 3, 2026: "CONMED agrees to buy back 2.250% convertible notes due 2027 for cash". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Jun 3, 2026: "CONMED agrees to buy back 2.250% convertible notes due 2027 for cash". The story links the filing or release it is based on. Read the story.
CONMED Corp trades under the ticker CNMD on NYSE.
CONMED Corp is listed on NYSE.
Our directory records CONMED Corp under United States.
aibio.space lists CONMED Corp among 2,820 public biotech companies and publishes its news here as stories appear.
$1.37 billion for the fiscal year ended Dec 31, 2025, as reported to the SEC.
CONMED Corp reported net income of $47.1 million for the fiscal year ended Dec 31, 2025, and generated $170.7 million of cash from operations, per its annual report to the SEC.
$55.9 million in the fiscal year ended Dec 31, 2025, per its annual report.
$48.0 million in cash at Sep 30, 2026, per its 10-Q.
Our latest story on CONMED, dated Jun 3, 2026: "CONMED agrees to buy back 2.250% convertible notes due 2027 for cash". CONMED will repurchase its 2.250% convertible notes due 2027 for cash under a purchase agreement dated June 3, 2026, with closing set for June 15, 2026. The principal and cash amounts sit in an exhibit the filing does not show. Source.
Press Follow on this page to add CONMED to your Following list, or subscribe to the aibio.space newsletter. We have published 2 stories naming CONMED so far, in Debt Financing.
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio